Krilogy Financial LLC decreased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 35.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,025 shares of the specialty pharmaceutical company’s stock after selling 575 shares during the quarter. Krilogy Financial LLC’s holdings in Jazz Pharmaceuticals were worth $150,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of JAZZ. Toronto Dominion Bank raised its holdings in Jazz Pharmaceuticals by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after acquiring an additional 81 shares in the last quarter. US Bancorp DE raised its holdings in Jazz Pharmaceuticals by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 368 shares in the last quarter. Gargoyle Investment Advisor L.L.C. acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $206,000. Advisor Group Inc. raised its holdings in Jazz Pharmaceuticals by 62.4% in the third quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after acquiring an additional 550 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $211,000. 91.30% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals PLC (JAZZ) opened at $140.00 on Tuesday. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. The stock has a market cap of $8,331.32, a P/E ratio of 17.44, a PEG ratio of 0.90 and a beta of 0.98. Jazz Pharmaceuticals PLC has a 1 year low of $101.44 and a 1 year high of $163.75.

Several analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Sunday, December 3rd. BMO Capital Markets reissued a “buy” rating and set a $196.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, September 20th. Mizuho raised their price objective on shares of Jazz Pharmaceuticals from $144.00 to $150.00 and gave the stock a “neutral” rating in a report on Tuesday, December 5th. Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 28th. They set a “neutral” rating and a $165.00 price objective on the stock. Finally, B. Riley reissued a “buy” rating and set a $206.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 5th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $181.28.

In other news, SVP Iain Mcgill sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the transaction, the senior vice president now directly owns 28,383 shares in the company, valued at $3,786,859.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Patrick G. Enright sold 352 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.19, for a total transaction of $46,882.88. Following the transaction, the director now owns 1,365 shares in the company, valued at $181,804.35. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,352 shares of company stock worth $1,264,243. Insiders own 4.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Krilogy Financial LLC Has $150,000 Position in Jazz Pharmaceuticals PLC (JAZZ)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/12/krilogy-financial-llc-has-150000-position-in-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.